The growing field of flow chemistry has the potential to cut down reaction times, reduce waste, increase reproducibility, and streamline process development time compared to traditional batch chemistry. Recently we embarked on a program to design and develop a flow synthesis system capable of synthesizing a wide range of organic target compounds. Described here is the development of a flow chemistry approach to imatinib, a compound used for the treatment of chronic myeloid leukemia. A continuous two-step synthesis of imatinib from 4-(chloromethyl)benzoyl chloride was achieved with no intermediate purification. The synthesis has been successfully demonstrated on both a commercial flow chemistry system and our in-house continuous synthesis system, AutoSyn<sup>TM</sup>. The process on AutoSyn<sup>TM</sup> was monitored online with UHPLC-MS and flow NMR to measure the composition of the flow stream. The process proved highly reproducible and enabled access to multigram amounts of imatinib.

Multistep continuous flow synthesis of imatinib

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.